KCM
ALNY icon

KRS Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

KRS Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-450
Closed -$205K – 116
2025
Q3 		$205K Buy
+450
New +$183K 0.12% 111
2022
Q1 		– Sell
-200
Closed -$33K – 125
2021
Q4 		$33K Buy
+200
New +$37.2K 0.03% 256

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

KRS Capital Management's ALNY Position: Q4 2025 in Review

KRS Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 450 shares — an estimated $205K sold.

KRS Capital Management first reported a position in ALNY in Q4 2021 and held it in 2 quarters. The position peaked at $205K in Q3 2025. 849 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • KRS Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • KRS Capital Management sold 450 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $205K.
  • KRS Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • KRS Capital Management's Alnylam Pharmaceuticals position peaked at $205K in Q3 2025.
  • 849 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on KRS Capital Management's 13F filing for Q4 2025, filed 15 Jan 2026.